MoonLake Immunotherapeutics MLTX Debt-to-assets
Debt-to-assets at other companies
Other financials
Where this comes from
Calculated from MoonLake Immunotherapeutics’s reported figures.
Based on the most recent quarter.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's debt-to-assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's debt-to-assets?
- MoonLake Immunotherapeutics (MLTX) reported debt-to-assets of 0.3× in Q1 2026.
- How has MoonLake Immunotherapeutics's debt-to-assets changed year-over-year?
- MoonLake Immunotherapeutics's debt-to-assets increased by 70.3% year-over-year, from 0.1× to 0.3×.
- What is the long-term trend for MoonLake Immunotherapeutics's debt-to-assets?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's debt-to-assets has grown at a -42.2% compound annual growth rate (CAGR), from 1.6× to 0.2×.
- What does debt-to-assets mean?
- Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.